Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma
IUBMB Life · 2025
DOI: 10.1002/iub.2930 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Dong Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China. Hauptthemen laut MEDLINE: Gefitinib, Drug Resistance, Neoplasm, Machine Learning, Adenocarcinoma of Lung. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Key Projects on Technological Innovation and Application Development of Chongqing, National Natural Science Foundation of China, Science and Technology Commission and Health Commission joint medical research program of Chongqing.
Abstract (Originalsprache)
Gefitinib resistance (GR) presents a significant challenge in treating lung adenocarcinoma (LUAD), highlighting the need for alternative therapies. This study explores the genetic basis of GR to improve prediction, prevention, and treatment strategies. We utilized public databases to obtain GR gene sets, single‐cell data, and transcriptome data, applying univariate and multivariate regression analyses alongside machine learning to identify key genes and develop a predictive signature. The signature's performance was evaluated using survival analysis and time‐dependent ROC curves on internal and external datasets. Enrichment and tumor immune microenvironment analyses were conducted to understand the mechanistic roles of the signature genes in GR. Our analysis identified a robust 22‐gene signature with strong predictive performance across validation datasets. This signature was significantly associated with chromosomal processes, DNA replication, immune cell infiltration, and various immune scores based on enrichment and tumor microenvironment analyses. Importantly, the signature also showed potential in predicting the efficacy of immunotherapy in LUAD patients. Moreover, we identified alternative agents to gefitinib that could offer improved therapeutic outcomes for high‐risk and low‐risk patient groups, thereby guiding treatment strategies for gefitinib‐resistant patients. In conclusion, the 22‐gene signature not only predicts prognosis and immunotherapy efficacy in gefitinib‐resistant LUAD patients but also provides novel insights into non‐immunotherapy treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
ORCID-Profile: Hong Zheng
Förderung
- Key Projects on Technological Innovation and Application Development of Chongqing
- National Natural Science Foundation of China
- Science and Technology Commission and Health Commission joint medical research program of Chongqing
Zitieren
APA
Zhou, D., Zheng, Z., Li, Y., Zhang, J., Lu, X., Zheng, H., & Dai, J. (2025). Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma. IUBMB Life. https://doi.org/10.1002/iub.2930
Vancouver
Zhou D, Zheng Z, Li Y, Zhang J, Lu X, Zheng H, et al. Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma. IUBMB Life. 2025. doi:10.1002/iub.2930
BibTeX
@article{Zhou2025,
author = {Zhou, Dong and Zheng, Zhi and Li, Yanqi and Zhang, Jiao and Lu, Xiao and Zheng, Hong and Dai, Jigang},
title = {Integrated multi‐omics and machine learning reveal a gefitinib resistance signature for prognosis and treatment response in lung adenocarcinoma},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.2930}
}
EUVIMED